Nelson Lab, UIUC
@nelsonlab.bsky.social
We investigate how hormones and metabolic factors impact tumor progression. Our goal is to use this information to develop novel therapeutics for the treatment.
And - a news story on the event here:
www.wcia.com/news/champai...
www.wcia.com/news/champai...
www.wcia.com
October 16, 2025 at 2:23 PM
And - a news story on the event here:
www.wcia.com/news/champai...
www.wcia.com/news/champai...
Register here:
forms.illinois.edu/sec/50084012...
More information on the Cancer Research Advocacy Group here, including links to previous webinars:
cancer.illinois.edu/cancer-resea...
forms.illinois.edu/sec/50084012...
More information on the Cancer Research Advocacy Group here, including links to previous webinars:
cancer.illinois.edu/cancer-resea...
CRAG Seminar - Mental Health and Cancer: Tools to Navigate the Unknown
forms.illinois.edu
October 16, 2025 at 2:21 PM
Register here:
forms.illinois.edu/sec/50084012...
More information on the Cancer Research Advocacy Group here, including links to previous webinars:
cancer.illinois.edu/cancer-resea...
forms.illinois.edu/sec/50084012...
More information on the Cancer Research Advocacy Group here, including links to previous webinars:
cancer.illinois.edu/cancer-resea...
February 18, 2025 at 1:45 AM
Writeup at: cancer.illinois.edu/a-new-approa...
A New Approach to Fighting Breast Cancer: Researchers Identify Compound that May Help the Immune System Slow or Stop Tumor Growth | Cancer Center at Illinois
cancer.illinois.edu
February 18, 2025 at 1:41 AM
Writeup at: cancer.illinois.edu/a-new-approa...
In two back-to-back papers in Cancer Letters, we show that NR0B2 suppresses the inflammasome in myeloid immune cells, decreasing Treg expansion. We developed a new NR0B2 agonist that has significant efficacy against solid tumors in pre-clinical models.
doi.org/10.1016/j.ca...
doi.org/10.1016/j.ca...
doi.org/10.1016/j.ca...
doi.org/10.1016/j.ca...
Redirecting
doi.org
February 18, 2025 at 1:41 AM
In two back-to-back papers in Cancer Letters, we show that NR0B2 suppresses the inflammasome in myeloid immune cells, decreasing Treg expansion. We developed a new NR0B2 agonist that has significant efficacy against solid tumors in pre-clinical models.
doi.org/10.1016/j.ca...
doi.org/10.1016/j.ca...
doi.org/10.1016/j.ca...
doi.org/10.1016/j.ca...
2007 - Toronto!
December 8, 2024 at 12:31 AM
2007 - Toronto!